Head-to-head evidence
elecoglipron vs SAL0150
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
elecoglipron
Developed by AstraZeneca
NCT06579105 · Phase 2 · completed
Participants receiving AZD5004 or placebo were randomized and kept blinded to treatment; a semaglutide comparator arm was open-label but was not part of the primary comparison. The highest dose produced a substantially larger drop in HbA1c than placebo, meeting the trial's main goal.
Next expected readout: May 2028 · NCT07664553 (registry estimate)
SAL0150
Developed by Shenzhen Salubris Pharmaceuticals
NCT05782192 · Phase 3 · completed
The study was randomized, quadruple-masked, and included both active and placebo comparator groups, with 458 participants. Its primary endpoint was the surrogate measure of HbA1c change. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: elecoglipron's landscape · SAL0150's landscape